View Filing Data

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2012
Document and Entity Information
Entity Registrant Name	Sunshine Heart, Inc.
Entity Central Index Key	0001506492
Document Type	S-1
Document Period End Date	Sep. 30, 2012
Pre-Effective Amendment Number	1
Amendment Flag	false
Entity Filer Category	Smaller Reporting Company

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2009
Current assets
Cash and cash equivalents	$ 17,446	$ 6,563	$ 10,344	$ 12,350	$ 7,028
Accounts receivable, net				247
Other current assets	667	346		182
Total current assets	18,113	6,909		12,779
Property, plant and equipment	493	522		120
TOTAL ASSETS	18,606	7,431		12,899
Current liabilities
Accounts payable	1,590	1,857		696
Accrued salaries, wages, and other compensation	681	978		114
Total current liabilities	2,271	2,835		810
Total liabilities	2,271	2,835		810
Commitments and contingencies
Stockholders' equity
Preferred stock as of December 31, 2011 and December 31, 2010, $0.0001 par value per share; authorized 40,000,000 shares
Common stock as of December 31, 2011 and December 31, 2010, par value $0.0001 per share; authorized 100,000,000 shares; issued and outstanding 6,019,663 and 5,063,968, respectively	1	1		1
Additional paid-in capital	90,339	68,652		60,086
Accumulated other comprehensive income:
Foreign currency translation adjustment	1,183	1,132		995
Accumulated deficit	(75,188)	(65,189)		(48,993)
Total stockholders' equity	16,335	4,596		12,089	$ 7,071
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 18,606	$ 7,431		$ 12,899

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Condensed Consolidated Balance Sheets
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	40,000,000	40,000,000	40,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	9,247,388	6,019,663	5,063,968
Common stock, shares outstanding	9,247,388	6,019,663	5,063,968

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Condensed Consolidated Statements of Operations and Comprehensive Loss
Net sales		$ 407
Operating expenses
Selling, general and administrative	$ 5,363	2,598
Research and development	11,199	6,229
Total operating expenses	16,562	8,827
Loss from operations	(16,562)	(8,420)
Interest income	251	150
Loss before income taxes	(16,311)	(8,270)
Income tax benefit	(115)	(670)
Net loss	$ (16,196)	$ (7,600)
Basic and diluted loss per share (in dollars per share)	$ (2.98)	$ (2.63)
Weighted average shares outstanding-basic and diluted	5,442	2,885
Other comprehensive income
Foreign currency translation adjustments	$ 137	$ 623
Total comprehensive loss	$ (16,059)	$ (6,977)

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income Foreign Currency Translation Adjustment	Accumulated Deficit	Comprehensive Loss
Balance at Dec. 31, 2009	$ 7,071		$ 48,092	$ 372	$ (41,393)
Balance (in shares) at Dec. 31, 2009		2,696
Comprehensive loss:
Net loss	(7,600)				(7,600)	$ (7,600)
Foreign currency translation adjustment	623			623		623
Total comprehensive loss	(6,977)					(6,977)
Stock based compensation	78		78
Issuance of common stock, net	11,917	$ 1	11,916
Issuance of common stock, net (in shares)		2,368
Balance at Dec. 31, 2010	$ 12,089	$ 1	60,086	995	(48,993)
Balance (in shares) at Dec. 31, 2010	5,063,968	5,064
Comprehensive loss:
Net loss	$ (10,961)
Total comprehensive loss	(10,961)
Balance at Dec. 31, 2010	$ 12,089	$ 1	60,086	995	(48,993)
Balance (in shares) at Dec. 31, 2010	5,063,968	5,064
Comprehensive loss:
Net loss	$ (16,196)				(16,196)	(16,196)
Foreign currency translation adjustment	137			137		137
Total comprehensive loss	(16,059)					$ (16,059)
Stock based compensation	939		939
Issuance of common stock, net	7,627		7,627
Issuance of common stock, net (in shares)		955
Balance at Dec. 31, 2011	$ 4,596	$ 1	$ 68,652	$ 1,132	$ (65,189)
Balance (in shares) at Dec. 31, 2011	6,019,663	6,019
Comprehensive loss:
Net loss	$ (9,999)
Total comprehensive loss	(9,999)
Balance at Sep. 30, 2012	$ 16,335
Balance (in shares) at Sep. 30, 2012	9,247,388

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415241&loc=d3e4534-113899

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11149-113907

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6576910&loc=d3e11178-113907

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A91
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 39
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

Amount after tax and reclassification adjustments, resulting from the process of expressing in the reporting currency of the reporting entity those amounts that are denominated or measured in a different currency, and from transactions whose terms are denominated in a currency other than the entity's functional currency, which is attributable to the parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 29
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Cash provided used in operations:
Net loss	$ (3,296)	$ (4,672)	$ (9,999)	$ (10,961)	$ (16,196)	$ (7,600)
Adjustments to reconcile net loss to cash flows from operating activities:
Depreciation and amortization	36	4	98	25	50	32
Loss on disposal of plant and equipment			63	6
Stock based compensation expense			907	555	939	78
Expense for warrants issued in conjunction with service agreement			160
Changes in asset and liabilities:
Accounts receivable				259	258	(123)
Other current assets			(321)	(24)	(166)	(94)
Accounts payable and accrued expenses			(574)	480	2,026	496
Net cash used in operations			(9,666)	(9,660)	(13,089)	(7,211)
Cash flows used in investing activities:
Purchase of property and equipment			(132)	(34)	(451)	(7)
Net cash used in investing activities			(132)	(34)	(451)	(7)
Cash flows provided by financing activities:
Net proceeds from the sale of common stock			20,620	7,650	7,627	11,917
Net cash provided by financing activities			20,620	7,650	7,627	11,917
Effect of exchange rate changes on cash			61	38	126	623
Net increase (decrease) in cash and cash equivalents			10,883	(2,006)	(5,787)	5,322
Cash and cash equivalents - beginning of period			6,563	12,350	12,350	7,028
Cash and cash equivalents - end of period	$ 17,446	$ 10,344	$ 17,446	$ 10,344	$ 6,563	$ 12,350

Nature of Business and Significant Accounting Policies

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Nature of Business and Significant Accounting Policies

Nature of Business and Significant Accounting Policies

Note 1 - Nature of Business and Significant Accounting Policies

Nature of Business: Sunshine Heart, Inc. was founded in November 1999 and incorporated in Delaware in August 2002 and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. is located in St Leonards, New South Wales, Australia (together with Sunshine Heart, Inc., “we,” “our” or the “Company”). Our headquarters are located in Eden Prairie, MN. We are a medical device company developing innovative technologies for cardiac and coronary disease. The Company’s primary product, the C-Pulse® Heart Assist System, or C-Pulse Heart System, is an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure, which can be implanted using a minimally invasive procedure. The C-Pulse Heart System is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart’s pumping load.

We are in the process of pursuing regulatory approvals necessary to sell our system in the United States. We completed enrollment of our North American feasibility clinical trial in the first half of 2011. In November 2011, we announced the preliminary results of the six-month follow-up period for the feasibility study and we submitted the clinical data to the United States Food and Drug Administration, or FDA. In March 2012, the FDA notified us that it completed its review of the C-Pulse System feasibility trial data, concluded we met the applicable agency requirements, and indicated that we can move forward with an investigational device exemption, or IDE, application. In September 2012, we received conditional approval from the FDA for an IDE and expect to initiate our pivotal trial before the end of 2012, once the conditions to the approval have been removed.

We obtained CE Mark approval for the C-Pulse System in July 2012 and have taken initial steps to evaluate the market potential for our system in targeted countries that accept the CE Mark in anticipation of commencing commercial sales. In order to gain additional clinical data and support reimbursement in Europe, we also expect to initiate a post-market trial in Europe that will evaluate endpoints similar to those for our U.S. pivotal trial.

Our shares of common stock have been publicly traded in the U.S. on the NASDAQ since February 2012, and in the form of CHESS Depositary Interests, or CDIs, in Australia on the Australian Securities Exchange, or ASX, since September 2004.

Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern.

During the years ended December 31, 2011 and 2010 and through September 30, 2012, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2011, we had an accumulated deficit of $65,189 and we expect to incur losses for the foreseeable future. To date, the Company has been funded by private and public equity financings. Although we believe that we will be able to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably.

The Company’s ability to continue as a going concern is dependent on the Company’s ability to raise additional capital based on the achievement of existing milestones as and when required. Should the future capital raising not be successful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. All intercompany accounts and transactions between consolidated entities have been eliminated.

Unaudited Interim Consolidated Financial Information: The interim balance sheet as of September 30, 2012 and statements of operations and cash flows for the nine months ended September 30, 2012 and 2011 and related interim information contained in the notes to these financial statements are unaudited. The accompanying condensed consolidated financial statements have been prepared in accordance with Regulation S-X of the Securities Act of 1933, or Securities Act. In the opinion of management, such unaudited interim consolidated information has been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and includes all adjustments consisting of normal recurring accruals necessary for the fair presentation of this interim information when read in conjunction with the audited financial statements and notes thereto. Certain information and disclosures normally included in the financial statements have been condensed or omitted pursuant to such rules and regulations, although management believes that disclosures are adequate to make information presented not misleading. Results for the nine months ended September 30, 2012 are not necessarily indicative of the results that may be expected for the year ending December 31, 2012 or any other interim period or for any other future year.

Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 2,551,456 and 2,216,615 for the nine months ended September 30, 2012 and 2011, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company’s net loss in each of those periods.

Fair Value of Financial Instruments: Our financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities. We believe that the carrying amounts of the financial instruments approximate their respective current fair values due to their relatively short maturities.

Pursuant to the requirements of the Fair Value Measurements and Disclosures Topic of the Financial Accounting Standards Board, or FASB, Codification, the Company’s financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Level 2: Financial instruments lacking unadjusted, quoted prices from active market exchanges, including over the counter traded financial instruments. The prices for the financial instruments are determined using prices for recently traded financial instruments with similar underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield curves that are observable at commonly quoted intervals.

Level 3: Financial instruments that are not actively traded on a market exchange. This category includes situations where there is little, if any, market activity for the financial instrument. The prices are determined using significant unobservable inputs or valuation techniques.

All cash and cash equivalents are considered Level 1 measurements for all periods presented. We do not have any financial instruments classified as Level 2 or Level 3 and there were no movements between these categories.

Recently Adopted Accounting Pronouncements

In May 2011, the FASB issued an update to accounting guidance for improved fair value measurement and disclosures. The update represents converged guidance between U.S. GAAP and IFRS, resulting in common requirements for measuring fair value and for disclosing information about fair value measurements. This new guidance was effective for our fiscal year beginning January 1, 2012 and the adoption of this guidance did not have an impact on our financial position, results of operations or cash flows.

In June 2011, the FASB issued amended disclosure requirements for the presentation of comprehensive income. The amended guidance eliminates the option to present components of other comprehensive income (“OCI”) as part of the statement of changes in equity. Under the amended guidance, all changes in OCI are to be presented either in a single continuous statement of comprehensive income or in two separate but consecutive financial statements. We adopted these changes effective January 1, 2012 and applied retrospectively for all periods. There was no impact to the consolidated results as the amendments related only to changes in financial statement presentation.

There was no other accounting pronouncement adopted during the three-month period ended September 30, 2012 that had a material impact on our financial position, operating results or disclosures.

Recent Accounting Pronouncements to be Adopted

There were no new accounting pronouncements issued during the three-month period ended September 30, 2012 that are expected to have material impacts on our financial position, operating results or disclosures.

Note 1—Nature of Business and Significant Accounting Policies

Nature of Business: Sunshine Heart ("we" or the "Company") was founded in November 1999 and incorporated in Delaware in August 2002. We are headquartered in Eden Prairie, MN and have a wholly owned subsidiary, Sunshine Heart Company Pty Ltd, located in St Leonards, New South Wales, Australia. We are a medical device company developing innovative technologies for cardiac and coronary disease. The Company's primary product, the C-Pulse® Heart Assist System, is an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart's pumping load. The Company has received approval from the United States Food and Drug Administration to conduct a United States feasibility clinical trial with the C-Pulse System. Our shares of common stock in the form of CHESS Depositary Interests (CDIs) have been publicly traded in Australia on the Australian Securities Exchange (ASX) since September 2004.

Going Concern: The Company's financial statements have been prepared and presented on a basis assuming it continues as a going concern.

During the years ended December 31, 2011 and 2010, the Company incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. At December 31, 2011, we had an accumulated deficit of $65.2 million and we expect to incur losses for the foreseeable future. To date, we have been funded by private and public equity financings. Although we believe that we will be able to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably.

The Company's ability to continue as a going concern is dependent on the Company's ability to raise additional capital based on the achievement of existing milestones as and when required. Should the future capital raising not be successful, the Company may not be able to continue as a going concern. Furthermore, the ability of the Company to continue as a going concern is subject to the ability of the Company to develop and successfully commercialize the product being developed. If the Company is unable to obtain such funding of an amount and timing necessary to meet its future operational plans, or to successfully commercialize its intellectual property, the Company may be unable to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, "Sunshine Heart" or the "Company"). All inter-company accounts and transactions between consolidated entities have been eliminated.

Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Pursuant to the requirements of the Fair Value Measurements and Disclosures Topic of the FASB Codification, the Company's financial assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Cash and Cash Equivalents: Cash and cash equivalents consist of cash, money market funds and term deposits with original maturities of three months or less. The carrying value of these instruments approximates fair value. The balances, at times, may exceed federally insured limits. We have not experienced any losses on our cash and cash equivalents.

Accounts Receivable: Accounts receivable are unsecured, are recorded at net realizable value, and do not bear interest. We make judgments as to our ability to collect outstanding receivables based upon significant patterns of uncollectiblity, historical experience, and managements' evaluation of specific accounts and will provide an allowance for credit losses when collection becomes doubtful. The Company performs credit evaluations of its customers' financial condition on an as-needed basis. Payment is generally due 30 days from the invoice date and accounts past 30 days are individually analyzed for collectability. When all collection efforts have been exhausted, the account is written off against the related allowance. No allowance for doubtful accounts was considered necessary as of December 31, 2011 or December 31, 2010.

Other Current Assets: Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment: Property and equipment is stated at cost less accumulated depreciation. Depreciation is computed based upon the estimated useful lives of the respective assets. Leasehold improvements are amortized using the straight-line method over the shorter of the lease term or the estimated useful life of the assets. Repairs and maintenance costs are expensed as incurred. Major betterments and improvements, which extend the useful life of the item, are capitalized and depreciated. The cost and accumulated depreciation of property, plant and equipment retired or otherwise disposed of are removed from the related accounts, and any residual values are charged or credited to expenses. Depreciation expense has been calculated using the following estimated useful lives:


Office furniture and equipment		5-15 years
Computer software and equipment		3-4 years
Laboratory and research equipment		3-15 years
Production equipment		7 years

Depreciation expense was $49 and $32 for the years ended December 31, 2011 and 2010, respectively.

Impairment of Long-lived Assets: Long-lived assets, such as property and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If the impairment tests indicate that the carrying value of the asset is greater than the expected undiscounted cash flows to be generated by such asset, an impairment loss would be recognized. The impairment loss is determined as the amount by which the carrying value of such asset exceeds its fair value. We generally measure fair value by considering sale prices for similar assets or by discounting estimated future cash flows from such assets using an appropriate discount rate. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets, and accordingly, actual results could vary significantly from such estimates. There have been no impairment losses for long-lived assets, for the years ended December 31, 2011 and 2010.

Revenue Recognition: We recognize revenue when (i) persuasive evidence of a customer arrangement exists; (ii) the price is fixed or determinable and free of contingencies or uncertainties; (iii) collectability is reasonably assured; and (iv) product delivery has occurred, which is when product title transfers to the customer, or services have been rendered. Sales are not conditional based on customer acceptance provisions or installation obligations. Our C-Pulse Heart Assist System is not approved for commercial sale. Our revenue consists solely of sales of the C-Pulse to hospitals and clinics under contract in conjunction with our clinical trials. For clinical trial implant revenue, the product title generally transfers on the date the product is implanted. We do not charge hospitals and clinics for shipping. We expense shipping costs at the time we report the related revenue and record them in cost of sales.

Foreign Currency Translation and Transactions: Foreign denominated monetary assets and liabilities are translated at the rate of exchange prevailing at the balance sheet date. Results of operations are translated using the average rates prevailing during the reporting period. The translation adjustment has not been included in determining the Company's net loss, but has been reported separately and is accumulated in a separate component of equity. Effective January 1, 2011, we concluded that the functional currency of our United States based parent company is the U.S. Dollar. Prior to that date the functional currency of both the United States based parent company and the Company's Australian subsidiary was the Australian dollar. For financial reporting purposes, the reporting currency of the company is the U.S. Dollar. When a transaction is denominated in a currency other than the entity's functional currency, the Company recognizes a transaction gain or loss in net earnings.

Comprehensive Income (Loss): The components of comprehensive income (loss) include net income (loss) and the effects of foreign currency translation adjustments.

Stock-Based Compensation: The Company recognizes all share-based payments, including grants of stock options, to in the income statement as an operating expense, based on their fair value over the requisite service period.

The Company computes the estimated fair values of stock options using the Black-Scholes option pricing model. No tax benefit has been recorded due to the full valuation allowance on deferred tax assets that the Company has recorded.

Stock-based compensation expense is based on awards ultimately expected to vest and is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Equity instruments issued to non-employees, and for services and goods are shares of the Company's common stock, warrants or options to purchase shares of the Company's common stock. These shares, warrants or options are either fully-vested and exercisable at the date of grant or vest over a certain period during which services are provided. The Company expenses the fair market value of these securities over the period in which the related services are received.

See Note 3 for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes: Deferred income taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards. Deferred tax liabilities are recognized for taxable temporary differences, which are the differences between the reported amounts of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 2,216,615 and 1,310,987 for the years ended December 31, 2011 and 2010, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company's net loss in each of those years.

Research and Development: Research and development expenses consist primarily of development personnel and non-employee contractor costs related to the development of new products and services, enhancement of existing products and services, quality assurance and testing. The Company incurred research and development expenses of $11,199 and $6,229 for the years ended December 31, 2011 and 2010, respectively.

Reverse Stock Split: On January 24, 2012, the board of directors declared a 1-for-200 reverse stock split and a corresponding inverse change in the transmutation ratio of CHESS Depositary Instruments ("CDIs") trading on the ASX in Australia such that one CDI will represent 1/200th of a share. The reverse split and change in transmutation ratio became effective for trading on the ASX on January 30, 2012. All share and per share data included in the consolidated financial statements and accompanying notes have been adjusted to reflect this reverse stock split.

Subsequent Events: The Company evaluates events through the date the financial statements are filed for events requiring adjustment to or disclosure in the financial statements. See Note 7, Subsequent Events for additional information.

New Accounting Pronouncements: In June 2011, the FASB issued amended disclosure requirements for the presentation of comprehensive income. The amended guidance eliminates the option to present components of other comprehensive income ("OCI") as part of the statement of changes in equity. Under the amended guidance, all changes in OCI are to be presented either in a single continuous statement of comprehensive income or in two separate but consecutive financial statements. We adopted these changes effective January 1, 2012 and applied retrospectively for all periods presented. There was no impact to the consolidated results as the amendments related only to changes in financial statement presentation.

In May 2011, FASB issued ASU 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in United States GAAP and IFRS. This accounting update generally aligns the principles for fair value measurements and the related disclosure requirements under United States GAAP and International Financial Reporting Standards. From a United States GAAP perspective, the amendments are largely clarifications, but some could have a significant effect on certain companies. A number of new disclosures also are required. Except for certain disclosures, the guidance applies to public and nonpublic companies and is to be applied prospectively. For public companies and nonpublic companies, the amendments are effective during interim and annual periods beginning after December 15, 2011. Early adoption by public companies is not permitted. Nonpublic companies may apply the amendments early, but no earlier than for interim periods beginning after December 15, 2011.

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References + Details

Balance Sheet Information

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Balance Sheet Information

Balance Sheet Information

Note 3 - Balance Sheet Information

Property, Plant and Equipment

Property, plant and equipment were as follows:

	September 30, 2012			December 31, 2011

Library	$	1		$	1
Office Furniture & Fixtures	98			177
Leasehold Improvements	145			251
Software	9			37
Production Equipment	384			293
Computer Equipment	141			134
Total	778			893
Accumulated Depreciation	(285		)	(371		)
	$	493		$	522

Depreciation expense for the three and nine month periods ended September 30, 2012 and 2011 was $36, $4, $98 and $25, respectively.

Note 2—Balance Sheet Information

Property, Plant and Equipment

Property, plant and equipment were as follows:

	December 31, 2011			December 31, 2010

Library	$	1		$	1
Office Furniture & Fixtures		177			90
Leasehold Improvements		251			78
Software		37			28
Production Equipment		293			179
Computer Equipment		134			65

Total		893			441
Accumulated Depreciation		(371	)		(321	)

	$	522		$	120

Equity

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Equity

Equity

Note 2 — Equity

Private Placement

On February 8, 2012 we placed 256,875 shares of common stock (in the form of CDIs) at AU$8.00 per share, for proceeds, net of transaction costs of $2,061.

Public Offering

On August 15, 2012 we sold 2,875,000 shares of common stock in a public offering at $7.00 per share and on August 20, 2012, we sold 94,800 shares of common stock upon the exercise of the over-allotment option by our underwriters at $7.00 per share. Proceeds in the public offering and exercise of the over-allotment option, net of transaction costs were $18,552 in the aggregate.

Stock-Based Compensation

The Company recognizes all share-based payments, including grants of stock options and compensatory employee stock purchase plans, in the income statement as an operating expense, based on their fair value over the requisite service period. We recorded $594 and $313 of related compensation expense to selling, general and administrative expense and research and development expense, respectively, for the nine months ended September 30, 2012, as compared to $385 and $170, respectively, of related compensation expense for the nine months ended September 30, 2011. As of September 30, 2012, a total of $3,321 of unrecognized compensation costs related to non-vested stock option awards was outstanding and is expected to be recognized within the next 3.5 fiscal years.

The Company uses the Black-Scholes option pricing model to determine the weighted average fair value of options. The volatility factor used in the Black-Scholes option pricing model is based on historical stock price fluctuations. The current forfeiture rate is based on a reasonable estimate by management. Expected dividend yield is based upon the Company’s historical and projected dividend activity and the risk free interest rate is based upon US Treasury rates appropriate for the expected term of the options. The expected term is based on estimates regarding projected employee stock option exercise behavior. Options for 31,875 shares were granted during the nine months ended September 30, 2012, and the weighted average fair value of these options was $196, determined using an expected dividend yield of 0%, an expected stock price volatility ranging from 98.3% to 98.6%, risk-free interest rates ranging from 1.38% to 1.43% and expected option lives of 6.5 years. There were no options granted in the nine months ended September 30, 2011.

The Company’s stock options generally vest over four years of service and have a contractual life of 10 years. We have 1,032,741 shares authorized for grant under our Amended and Restated 2011 Equity Incentive Plan.

Warrants

Warrants to purchase 1,664,599 and 1,496,032 shares of common stock were outstanding at September 30, 2012 and December 31, 2011, respectively.

As part of the private placement on February 8, 2012, we issued 77,063 warrants to purchase common stock at an exercise price of AU$11.20 per share and a term of 4 years, and 8,553 warrants to purchase common stock at an exercise price of AU$8.00 per share with a term of 5 years.

On September 7, 2012, we issued 100,000 non-forfeitable and fully exercisable warrants to purchase common stock at an exercise price of $7.00 per share and a term of 5 years, pursuant to a professional services agreement extending through June 2013.

During the nine months ended September 30, 2012, 1,050 warrants were exercised at a price of AU$6.40 per share for total proceeds of AU$7. These warrants were determined to have a fair value of $519, of which $160 was charged to expense during the third quarter 2012.

Note 3—Equity

Private Placement

In November and December, 2010, the Company placed 2,368,576 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $11,917.

In January 2011, the Company placed 17,858 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $99.

In July 2011, the Company placed 572,222 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $4,597.

In September 2011, the Company placed 349,444 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $2,838.

Stock Options

The Company recognized share-based compensation expense related to stock options and grants of common stock to employees, directors and consultants of $939 and $78 during the years ended December 31, 2011 and 2010, respectively. The following table summarizes the stock-based compensation expense which was recognized in the Consolidated Statements of Operations for the years ended December 31, 2011 and 2010:

	December 31, 2011		December 31, 2010

Selling, general and administrative	$	621	$	55
Research and development		318		23

Total	$	939	$	78

As of December 31, 2011 and December 31, 2010 the total compensation cost related to all nonvested awards not yet recognized was $4,582 and $94, respectively. This amount is expected to be recognized over the remaining weighted-average period of 9.21 years as of December 31, 2011 and 1.19 years as of December 31, 2010.

The Company has granted stock options to certain employees and directors under the Amended and Restated 2002 Stock Plan and its 2011 Equity Incentive Plan (collectively the "Plans"). The Plans are designed to assist in the motivation and retention of employees and to recognize the importance of employees to the long-term performance and success of the Company. The Company has also granted stock options to certain consultants outside of the Plans. The majority of the options to purchase common stock vest on the anniversary of the date of grant, which ranges from one to four years. Additionally, certain stock options vest upon the closing price of the Company's common stock reaching certain minimum levels, as defined in the agreements. Finally, certain other stock options vest upon the meeting of certain Company milestones such as the signing of specific agreements and the completion of the Company's anticipated listing on a United States stock exchange. As of December 31, 2011, the Company expects that all such market and performance conditions will be met. Share-based compensation expense related to these awards is recognized on a straight-line basis over the related vesting term. It is the Company's policy to issue new shares upon the exercise of options.

The following is a summary of the Plan and non-Plan stock option activity during the year ended December 31, 2011 and 2010.

		Weighted Average Exercise price			Aggregate Intrinsic Value

Outstanding, December 31, 2009	78,789	$	37.94
2010 Grants	50,000		10.72
2010 Exercises	—		—
2010 Forfeitures/expiration	2,091		36.70

Outstanding, December 31, 2010	126,698		28.00	7.26	$	819

Exercisable at December 31, 2010	90,427		6.94	6.54		819
2011 Grants	794,926		7.64
2011 Exercises	1,560		6.58
2011 Forfeitures/expiration	33,231		13.02

Outstanding, December 31, 2011	886,833	$	10.05	9.21	$	62,674

Exercisable at December 31, 2011	184,296	$	18.74	10.06	$	24,013

The aggregate intrinsic value is defined as the difference between the market value of the Company's common stock (based on the trading price of the Company's CDIs on ASX) as of the end of the period and the exercise price of the in-the-money stock options. The total intrinsic value of stock options exercised during the years ended December 31, 2011 and 2010 was $3 and $0, respectively. Of the 702,537 non vested options, 40 are held by consultants, the majority of which vest in 2012. Total cash proceeds from exercised options were $10 and $0 for the years ended December 31, 2011 and 2010, respectively.

The weighted-average fair value of stock options granted during the years ended December 31, 2011 and 2010 was $6.62 and $10.72, respectively.

The fair value of each stock option is estimated at the grant date using the Black-Scholes option pricing model. The Company has not historically paid dividends to its shareholders, and, as a result assumed a dividend yield of 0%. The 2011 risk free interest rate is based upon the rates of US Treasury bins with a term equal to the expected term of the option. The 2010 risk free interest rate is based upon the rates of Australian bonds with a term equal to the expected term of the option. The expected volatility is based upon the historical price of the Company's CDIs. The expected term of the stock options to purchase common stock is based upon the outstanding contractual expected life of the stock option on the date of grant. The Company used the following weighted-average assumptions in calculating the fair value of options granted during the years ended December 31, 2011 and 2010.

	Year ended December 31

	2011			2010
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.43	%		4.97	%
Expected volatility		100	%		65	%
Expected life (in years)		6.5			5

Warrants

Warrants to purchase 1,496,032 and 1,223,787 shares of common stock were outstanding at December 31, 2011 and 2010, respectively.

On November 10, 2010, the Company issued 357,050 warrants at an exercise price of AU$6.40 and a term of 4 years as part of the private placements previously described.

Also, as part of the private placements completed during 2010, the Company issued 850,737 warrants to purchase common stock at an exercise price of AU$6.40 per share. The warrants have a stated life of four years.

As part of the private placement completed during 2011, the Company issued 10,623 warrants to purchase common stock at an exercise price of AU$8.20 per share and 276,501 warrants to purchase common stock at an exercise price of AU$11.20 per share. The warrants have a stated life of four years.

Additional warrants to purchase common stock were issued in connection with the issuance of $800 convertible promissory notes in June 2004, which were issued as a bridging loan prior to the initial public offering of the Company's CDIs on the ASX. These warrants were issued to related party entities affiliated with certain directors of the Company and to one unrelated party. The warrants entitle the holders to receive 16,000 shares at an exercise price of AU$5.00. The warrants have an exercise period of ten years and expire in June 2014.

During the year ended December 31, 2011, 14,879 warrants were exercised at a price of AU$6.40 for total proceeds of $99.

Income Taxes

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Income Taxes

Income Taxes

Note 4 — Income Taxes

In June 2012, we received a $730 research and development tax credit refund, based upon qualified research and development expenditures of our Australian subsidiary for its tax period ended June 30, 2011. The Australian research and development tax credit is paid as a refundable credit to small and medium enterprises. We have not completed the Australian tax return for the period ended June 30, 2012; therefore, we have reflected no net benefit related to the Australian research and development tax credit for that period.

Note 4—Income Taxes

Domestic and foreign loss before provision for income taxes consists of the following:



Domestic	(11,252	)	(2,207	)
Foreign	(4,944	)	(5,563	)

Total	(16,196	)	(8,270	)

The components of income tax expense for the years ended December 31, 2011 and 2010 consist of the following:



Income tax provision:
Current:
United States and state	(115	)	—
Foreign	—		(670	)
Deferred:
United States and state	—		—
Foreign	—		—

Total income tax (benefit) expense	(115	)	(670	)

Actual income tax expense differs from statutory federal income tax benefit for the years ended December 31, 2011 and 2010 as follows:



Statutory federal income tax benefit	(5,555	)	(2,812	)
State tax benefit, net of federal taxes	(727	)	(417	)
Foreign tax	199		225
R&D tax credit rebate	(265	)	(670	)
Valuation allowance increase	6,121		3,033
Other	112		(29	)

Total income tax (benefit) expense	(115	)	(670	)

Deferred taxes as of December 31, 2011 and 2010 consist of the following:



Deferred tax assets (liabilities):
Accrued expenses	115		120
Stock based compensation	658		385
Capitalized patent costs	126		140
Deferred rent	78		—
Fixed assets	(76	)	—
R&D credits	150		—
Other	7		7
Net operating losses	22,357		16,210

	23,415		16,862
Less: valuation allowance	(23,415	)	(16,862	)

	—		—

As of December 31, 2011, we had United States net operating loss (NOL) carryforwards of approximately $14.6 million for U.S. income tax purposes, which expire in 2023 through 2031, and NOLs in the Commonwealth of Australia of approximately $54.1 million which we can carry forward indefinitely. United States net operating loss carryforwards cannot be used to offset taxable income in foreign jurisdictions. In addition, future utilization of net operating loss carryforwards in the United States may be subject to certain limitations under Section 382 of the Internal Revenue Code. This section generally relates to a 50 percent change in ownership of a company over a three-year period. No formal study has been prepared as of the balance sheet date to determine any applicable limitations on the utilization of the United States net operating losses.

We received a $670 fully refundable research and development tax credit in 2010, determined as a combined average of 44% of qualified research and development expenditures of our Australian subsidiary for its tax period ended June 30, 2010. The Australian research and development tax credit is paid as a refundable credit to small and medium enterprises for tax years ending on or before June 30, 2011, when total research and development expenses of the Australian subsidiary are less than A$2 million for the tax period. If total eligible research and development expenses exceed A$2 million, the tax credit is instead applied as a carryforward reduction against future income taxes. We have not completed the Australian tax return for the period ended June 30, 2011, and cannot be assured that our total eligible research and development expenses will be less than A$2 million. Therefore, we have reflected $0 net benefit related to the research and development credit for 2011. We also computed a $115 fully refundable research and development tax credit for the state of Minnesota for the fiscal year ended June 30, 2011. This credit is computed as a percentage of qualified research expenditures that were incurred in the state of Minnesota during the fiscal year. We have not yet completed a study to determine whether a similar credit will be generated for the six months ended December 31, 2011; therefore, we have reflected $0 net benefit related to the Minnesota research and development credit for the six months ended December 31, 2011.

We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a valuation allowance for United States and foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying financial statements. For the years ended December 31, 2011 and 2010, the valuation allowance increased by $6.6 million and $4.5 million, respectively. Changes in the valuation allowance do not equal the amounts reflected in the statutory rate reconciliation due to fluctuating currency exchange rates.

The Company has adopted accounting guidance related to uncertain tax positions. This accounting guidance prescribes a recognition threshold and measurement attribute for recognition and measurement of a tax position taken or expected to be taken in a tax return. It also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The adoption of uncertain tax position guidance did not have a material impact on the Company's consolidated financial statements. Additionally, the adoption of the guidance had no impact on retained earnings. The Company had no material uncertain tax positions as of December 31, 2011 or December 31, 2010.

We recognize interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. Upon adoption of this guidance, we recognized no interest or penalties related to uncertain tax positions. During the years ended December 31, 2011 and 2010 we recorded no accrued interest or penalties related to uncertain tax positions.

The fiscal tax years ended June 30, 2008 through December 31, 2011 remain open to examination by the Internal Revenue Service. For the states of California and Minnesota, all years subsequent to the fiscal tax year ended June 30, 2006 are also open to examination. Additionally, the returns of the Company's Australian subsidiary are subject to examination by Australian tax authorities for the fiscal tax years ended June 30, 2007 through June 30, 2011.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Commitments and Contingencies

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies

Commitments and Contingencies

Note 5—Commitments and Contingencies

Leases

We lease office space under non-cancelable operating leases that expire at various times through March 2016. Rent expense related to operating leases was approximately $274 and $186 for the years ended December 31, 2011 and 2010, respectively. Future minimum lease payments under non-cancelable operating leases as of December 31, 2011 were approximately $260, $194, $262, $267 and $67 for each the years ended December 31, 2012, through 2016, respectively.

Employee Benefits

All Australian employees are entitled to varying levels of benefits on retirement, disability or death. The superannuation plans provide accumulated benefits. Employees contribute to the plans at various percentages of their wages and salaries. Contributions by the Company of up to 9% of employees' wages and salaries are legally enforceable in Australia. For the years ended December 31, 2011 and 2010, the Company incurred expense of $82 and $64, respectively.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Related Party Transaction

12 Months Ended

Dec. 31, 2011

Related Party Transaction

Related Party Transaction

Note 6—Related Party Transaction

During the year ended December 31, 2011 and 2010, we paid $9 and $4 to SCP Technology and Growth Pty Limited, a company controlled by a director of our Australian subsidiary, for the provision of intellectual property and patent services. There were no amounts outstanding to this entity at December 31, 2011 or December 31, 2010. In September 2011, we sold 14,375 shares of our common stock to Jeffrey Mathiesen, our Chief Financial Officer, at the price of A$8.00 per share as part of a private placement.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events

12 Months Ended

Dec. 31, 2011

Subsequent Events

Subsequent Events

Note 7—Subsequent Events

On February 9, 2012, we placed 259,000 shares of common stock for proceeds, net of transaction costs, of $2.1 million.

On February 14, 2012, the SEC certified our common shares for listing on The Nasdaq Stock Exchange, effective that same day. Our common shares began trading on The Nasdaq Capital Market on February 16, 2012 under the symbol "SSH."

Segment and Geographic Information

12 Months Ended

Dec. 31, 2011

Segment and Geographic Information

Segment and Geographic Information

Note 8—Segment and Geographic Information

The Company has one reportable segment, cardiac and coronary disease products. The Company's geographic regions include the United States and Australia.

Revenue earned relating to reimbursement of clinical trials is earned primarily in the United States. Interest income is primarily earned in Australia.

Long-lived assets are located primarily in the United States at December 31, 2011.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Nature of Business and Significant Accounting Policies (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Nature of Business and Significant Accounting Policies

Nature of Business

Going Concern

Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Going Concern: The Company's financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Basis of Presentation

Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, "Sunshine Heart" or the "Company"). All inter-company accounts and transactions between consolidated entities have been eliminated.

Use of Estimates

Fair Value of Financial Instruments

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Cash and Cash Equivalents

Accounts Receivable

Other Current Assets

Other Current Assets: Other current assets represent prepayments and deposits made by the Company.

Property, Plant and Equipment


Office furniture and equipment		5-15 years
Computer software and equipment		3-4 years
Laboratory and research equipment		3-15 years
Production equipment		7 years

Depreciation expense was $49 and $32 for the years ended December 31, 2011 and 2010, respectively.

Impairment of Long-lived Assets

Revenue Recognition

Foreign Currency Translation and Transactions

Comprehensive Income (Loss)

Comprehensive Income (Loss): The components of comprehensive income (loss) include net income (loss) and the effects of foreign currency translation adjustments.

Stock-Based Compensation

See Note 3 for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Income Taxes

Net Loss per Share

Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 2,216,615 and 1,310,987 for the years ended December 31, 2011 and 2010, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company's net loss in each of those years.

Research and Development

Reverse Stock Split

Subsequent Events

New Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There was no other accounting pronouncement adopted during the three-month period ended September 30, 2012 that had a material impact on our financial position, operating results or disclosures.

Recent Accounting Pronouncements to be Adopted

Nature of Business and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2011

Nature of Business and Significant Accounting Policies

Schedule of estimated useful lives


Office furniture and equipment		5-15 years
Computer software and equipment		3-4 years
Laboratory and research equipment		3-15 years
Production equipment		7 years

Balance Sheet Information (Tables)

12 Months Ended

Dec. 31, 2011

Balance Sheet Information

Schedule of property, plant and equipment

	December 31, 2011			December 31, 2010

Library	$	1		$	1
Office Furniture & Fixtures		177			90
Leasehold Improvements		251			78
Software		37			28
Production Equipment		293			179
Computer Equipment		134			65

Total		893			441
Accumulated Depreciation		(371	)		(321	)

	$	522		$	120

Equity (Tables)

12 Months Ended

Dec. 31, 2011

Equity

Summary of stock-based compensation expense

	December 31, 2011		December 31, 2010

Selling, general and administrative	$	621	$	55
Research and development		318		23

Total	$	939	$	78

Summary of the Plan and non-Plan stock option activity

		Weighted Average Exercise price			Aggregate Intrinsic Value

Outstanding, December 31, 2009	78,789	$	37.94
2010 Grants	50,000		10.72
2010 Exercises	—		—
2010 Forfeitures/expiration	2,091		36.70

Outstanding, December 31, 2010	126,698		28.00	7.26	$	819

Exercisable at December 31, 2010	90,427		6.94	6.54		819
2011 Grants	794,926		7.64
2011 Exercises	1,560		6.58
2011 Forfeitures/expiration	33,231		13.02

Outstanding, December 31, 2011	886,833	$	10.05	9.21	$	62,674

Exercisable at December 31, 2011	184,296	$	18.74	10.06	$	24,013

Schedule of weighted-average assumptions used in calculating the fair value of options granted

	Year ended December 31

	2011			2010
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.43	%		4.97	%
Expected volatility		100	%		65	%
Expected life (in years)		6.5			5

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2011

Income Taxes

Schedule of domestic and foreign loss before provision for income taxes



Domestic	(11,252	)	(2,207	)
Foreign	(4,944	)	(5,563	)

Total	(16,196	)	(8,270	)

Schedule of components of income tax expense



Income tax provision:
Current:
United States and state	(115	)	—
Foreign	—		(670	)
Deferred:
United States and state	—		—
Foreign	—		—

Total income tax (benefit) expense	(115	)	(670	)

Summary showing actual income tax expense differing from statutory federal income tax benefit



Statutory federal income tax benefit	(5,555	)	(2,812	)
State tax benefit, net of federal taxes	(727	)	(417	)
Foreign tax	199		225
R&D tax credit rebate	(265	)	(670	)
Valuation allowance increase	6,121		3,033
Other	112		(29	)

Total income tax (benefit) expense	(115	)	(670	)

Schedule of components of deferred taxes



Deferred tax assets (liabilities):
Accrued expenses	115		120
Stock based compensation	658		385
Capitalized patent costs	126		140
Deferred rent	78		—
Fixed assets	(76	)	—
R&D credits	150		—
Other	7		7
Net operating losses	22,357		16,210

	23,415		16,862
Less: valuation allowance	(23,415	)	(16,862	)

	—		—

Nature of Business and Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Sep. 30, 2012
Going Concern
Accumulated deficit	$ 65,189	$ 48,993	$ 75,188
Accounts Receivable
Period of payment due from the invoice date	30 days
Property, Plant and Equipment
Depreciation expense	$ 49	$ 32
Office furniture and equipment \| Minimum
Property, Plant and Equipment
Estimated useful lives	5 years
Office furniture and equipment \| Maximum
Property, Plant and Equipment
Estimated useful lives	15 years
Computer software and equipment \| Minimum
Property, Plant and Equipment
Estimated useful lives	3 years
Computer software and equipment \| Maximum
Property, Plant and Equipment
Estimated useful lives	4 years
Laboratory and research equipment \| Minimum
Property, Plant and Equipment
Estimated useful lives	3 years
Laboratory and research equipment \| Maximum
Property, Plant and Equipment
Estimated useful lives	15 years
Production equipment
Property, Plant and Equipment
Estimated useful lives	7 years

Nature of Business and Significant Accounting Policies (Details 2) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2012	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Sep. 30, 2012 USD ($) shares	Sep. 30, 2011 USD ($) shares	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares
Research and Development
Research and Development Expense \| $		$ 1,802	$ 3,273	$ 5,755	$ 7,939	$ 11,199	$ 6,229
Reverse Stock Split
Reverse stock transmutation ratio	0.005
Stock warrants
Antidilutive securities
Outstanding stock excluded from the computation of loss per share as their effect was antidilutive (in shares)				2,551,456	2,551,456	2,216,615	2,216,615
Stock options
Antidilutive securities
Outstanding stock excluded from the computation of loss per share as their effect was antidilutive (in shares)				2,216,615	2,216,615	1,310,987	1,310,987

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References + Details

Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment
Total	$ 778	$ 893	$ 441
Accumulated Depreciation	(285)	(371)	(321)
Property, plant and equipment, net	493	522	120
Library
Property, Plant and Equipment
Total	1	1	1
Office Furniture & Fixtures
Property, Plant and Equipment
Total	98	177	90
Leasehold Improvements
Property, Plant and Equipment
Total	145	251	78
Software
Property, Plant and Equipment
Total	9	37	28
Production Equipment
Property, Plant and Equipment
Total	384	293	179
Computer Equipment
Property, Plant and Equipment
Total	$ 141	$ 134	$ 65

Equity (Details) - USD ($) $ in Thousands			1 Months Ended				2 Months Ended	9 Months Ended		12 Months Ended
Equity (Details) - USD ($) $ in Thousands	Aug. 15, 2012	Feb. 08, 2012	Aug. 31, 2012	Sep. 30, 2011	Jul. 31, 2011	Jan. 31, 2011	Dec. 31, 2010	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Private Placement
Common stock placed (in shares)	2,875,000	256,875		349,444	572,222	17,858	2,368,576
Proceeds from private placement offering net of transaction costs		$ 2,061	$ 18,552	$ 2,838	$ 4,597	$ 99	$ 11,917	$ 20,620	$ 7,650	$ 7,627	$ 11,917
Stock-Based Compensation
Compensation expense										939	78
Selling, general and administrative
Stock-Based Compensation
Compensation expense								594	385	621	55
Research and development
Stock-Based Compensation
Compensation expense								$ 313	$ 170	$ 318	$ 23

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References + Details

Equity (Details 2) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock-Based Compensation
Unrecognized compensation cost related to non-vested stock option awards	$ 3,321	$ 4,582	$ 94
Unrecognized compensation cost related to non-vested stock option awards, recognition period	3 years 6 months	9 years 2 months 16 days	1 year 2 months 8 days
Vesting period of options	4 years
Options Outstanding
Outstanding at the beginning of the period (in shares)	886,833	126,698	78,789
Grants (in shares)		794,926	50,000
Exercises (in shares)		1,560
Forfeitures/expiration (in shares)		33,231	2,091
Outstanding at the end of the period (in shares)		886,833	126,698
Exercisable at the end of the period (in shares)		184,296	90,427
Weighted Average Exercise price
Outstanding at the beginning of the period (in dollars per share)	$ 10.05	$ 28.00	$ 37.94
Grants (in dollars per share)		7.64	10.72
Exercises (in dollars per share)		6.58
Forfeitures/expiration (in dollars per share)		13.02	36.70
Outstanding at the end of the period (in dollars per share)		10.05	28.00
Exercisable at the end of the period (in dollars per share)		$ 18.74	$ 6.94
Remaining Average Contractual Term
Outstanding at the end of the period		9 years 2 months 16 days	7 years 3 months 4 days
Exercisable at the end of the period		10 years 22 days	6 years 6 months 14 days
Aggregate Intrinsic Value
Outstanding at the end of the period (in dollars)		$ 62,674	$ 819
Exercisable at the end of the period (in dollars)		24,013	819
Total intrinsic value		$ 3	0
Additional disclosures
Nonvested options (in shares)		702,537
Nonvested options held by consultants (in shares)		40
Cash proceeds from exercised options		$ 10	$ 0
Weighted-average fair value of options granted (in dollars per share)		$ 6.62	$ 10.72
Weighted-average assumptions used in calculating the fair value of options granted
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Risk-free interest rate (as a percent)		1.43%	4.97%
Expected stock price volatility (as a percent)		100.00%	65.00%
Expected life	6 years 6 months	6 years 6 months	5 years
Minimum
Stock-Based Compensation
Vesting period of options		1 year
Weighted-average assumptions used in calculating the fair value of options granted
Risk-free interest rate (as a percent)	1.38%
Expected stock price volatility (as a percent)	98.30%
Maximum
Stock-Based Compensation
Vesting period of options		4 years
Weighted-average assumptions used in calculating the fair value of options granted
Risk-free interest rate (as a percent)	1.43%
Expected stock price volatility (as a percent)	98.60%

Equity (Details 3) $ in Thousands, $ in Thousands	1 Months Ended		9 Months Ended	12 Months Ended
Equity (Details 3) $ in Thousands, $ in Thousands	Nov. 30, 2010	Jun. 30, 2004 USD ($) item $ / shares shares	Sep. 30, 2012 AUD ($) $ / shares shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 $ / shares shares	Nov. 10, 2010 $ / shares shares
Warrants
Warrants outstanding (in shares)			1,664,599	1,496,032	1,223,787
Warrants issued (in shares)			1,050
Exercise price of warrants (in dollars per share) \| $ / shares			6.40
Total proceeds on exercise of warrants \| $			$ 7
Convertible promissory notes
Warrants
Notes issued (in dollars) \| $		$ 800
Number of unrelated parties \| item		1
Exercise price of AU$8.20
Warrants
Warrants issued (in shares)				10,623
Exercise price of warrants (in dollars per share) \| $ / shares				8.20
Term of warrants				4 years
Exercise price of AU$11.20
Warrants
Warrants issued (in shares)				276,501
Exercise price of warrants (in dollars per share) \| $ / shares				11.20
Term of warrants				4 years
Exercise price of AU$6.40
Warrants
Warrants issued (in shares)					850,737	357,050
Exercise price of warrants (in dollars per share) \| $ / shares				6.40	6.40	6.40
Term of warrants	4 years				4 years
Warrants exercised (in shares)				14,879
Total proceeds on exercise of warrants \| $				$ 99
Exercise price of AU$5.00 \| Convertible promissory notes
Warrants
Warrants issued (in shares)		16,000
Exercise price of warrants (in dollars per share) \| $ / shares		5.00
Term of warrants		10 years

Income Taxes (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Income Taxes
Domestic						$ (11,252)	$ (2,207)
Foreign						(4,944)	(5,563)
Loss before income taxes		$ (3,296)	$ (4,672)	$ (10,729)	$ (10,961)	(16,311)	(8,270)
Current:
United States and state						(115)
Foreign						0	(670)
Deferred:
United States and state						0
Foreign						0
Total income tax (benefit) expense	$ (730)			$ (730)		(115)	(670)
Income tax reconciliation
Statutory federal income tax benefit						(5,555)	(2,812)
State tax benefit, net of federal taxes						(727)	(417)
Foreign tax						199	225
R&D tax credit rebate						(265)	(670)
Valuation allowance increase						6,121	3,033
Other						112	(29)
Total income tax (benefit) expense						(115)	(670)
Deferred tax assets (liabilities):
Accrued expenses						115	120
Stock based compensation						658	385
Capitalized patent costs						126	140
Deferred rent						78
Fixed assets						(76)
R&D credits						150
Other						7	7
Net operating losses						22,357	16,210
Deferred tax assets (liabilities) before valuation allowances						23,415	16,862
Less: valuation allowance						(23,415)	$ (16,862)
Deferred tax assets (liabilities)						$ 0

Income Taxes (Details 2) $ in Millions	12 Months Ended
Income Taxes (Details 2) $ in Millions	Dec. 31, 2011 USD ($)
United States
Operating loss carryforwards
Net operating loss (NOL) carryforwards	$ 14.6
Percentage of cumulative change in ownership which may substantially limit the annual utilization of the entity's net operating loss carryforwards	50.00%
Period over which cumulative change in percentage of ownership is considered for determining the limitation on the annual utilization of the entity's net operating loss and tax credit carryforwards	3 years
Commonwealth of Australia
Operating loss carryforwards
Net operating loss (NOL) carryforwards	$ 54.1

Income Taxes (Details 3) $ in Thousands, $ in Millions	1 Months Ended	6 Months Ended		9 Months Ended	12 Months Ended
Income Taxes (Details 3) $ in Thousands, $ in Millions	Jun. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)	Jun. 30, 2010	Sep. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2011 USD ($)	Jun. 30, 2011 AUD ($)
Tax credit carryforward
Tax credit	$ (730)			$ (730)	$ (115)	$ (670)
Increase in valuation allowance					6,600	4,500
Research and development tax credit
Tax credit carryforward
Tax credit					$ 0
Research and development tax credit \| State of Minnesota
Tax credit carryforward
Tax credit							$ 115
Tax credit		$ 0
Research and development tax credit \| Australian subsidiary \| Australian
Tax credit carryforward
Tax credit						$ 670
Percentage of qualified research and development expenditures			44.00%
Maximum research and development expenses for refundable credit								$ 2.0

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Commitments and Contingencies
Rent expense related to operating leases	$ 274	$ 186
Future minimum lease payments
2012	260
2013	194
2014	262
2015	267
2016	$ 67
Employee Benefits
Contribution by the company as percentage of employees wages and salaries	9.00%
Expenses incurred	$ 82	$ 64

Related Party Transaction (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares	Sep. 30, 2012 shares	Aug. 20, 2012 $ / shares	Aug. 15, 2012 $ / shares	Feb. 08, 2012 $ / shares	Sep. 30, 2011 $ / shares shares
Related Party Transaction
Common stock sold (in shares)	6,019,663	5,063,968	9,247,388
Common stock offering price (in dollars per share) \| (per share)				$ 7.00	$ 7.00	$ 8.00
SCP Technology and Growth Pty Limited
Related Party Transaction
Amount paid to related party for the provision of intellectual property and patent services \| $	$ 9	$ 4
Jeffrey Mathiesen
Related Party Transaction
Common stock sold (in shares)							14,375
Common stock offering price (in dollars per share) \| $ / shares							$ 8.00

Subsequent Events (Details) - USD ($) $ in Thousands			1 Months Ended					2 Months Ended	9 Months Ended		12 Months Ended
Subsequent Events (Details) - USD ($) $ in Thousands	Aug. 15, 2012	Feb. 08, 2012	Aug. 31, 2012	Feb. 28, 2012	Sep. 30, 2011	Jul. 31, 2011	Jan. 31, 2011	Dec. 31, 2010	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Subsequent Events
Common stock placed (in shares)	2,875,000	256,875			349,444	572,222	17,858	2,368,576
Proceeds from private placement offering net of transaction costs		$ 2,061	$ 18,552		$ 2,838	$ 4,597	$ 99	$ 11,917	$ 20,620	$ 7,650	$ 7,627	$ 11,917
Subsequent events
Subsequent Events
Common stock placed (in shares)				259,000
Proceeds from private placement offering net of transaction costs				$ 2,100

Segment and Geographic Information (Details)	12 Months Ended
Segment and Geographic Information (Details)	Dec. 31, 2011 item
Segment and Geographic Information
Number of reportable segments	1

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2011	Dec. 31, 2010	Dec. 31, 2009
Current assets
Cash and cash equivalents	$ 17,446	$ 6,563	$ 10,344	$ 12,350	$ 7,028
Accounts receivable, net				247
Other current assets	667	346		182
Total current assets	18,113	6,909		12,779
Property, plant and equipment, net	493	522		120
TOTAL ASSETS	18,606	7,431		12,899
Current liabilities
Accounts payable	1,590	1,857		696
Accrued salaries, wages, and other compensation	681	978		114
Total current liabilities	2,271	2,835		810
Total liabilities	2,271	2,835		810
Commitments and contingencies
Stockholders' equity
Preferred Stock as of September 30, 2012 and December 31, 2011, par value $0.0001 per share; authorized 40,000,000 shares
Common stock as of September 30, 2012 and December 31, 2011, par value $0.0001 per share; authorized 100,000,000 shares: issued and outstanding 9,247,388 and 6,019,663 shares, respectively	1	1		1
Additional paid-in capital	90,339	68,652		60,086
Accumulated other comprehensive loss:
Foreign currency translation adjustment	1,183	1,132		995
Retained earnings	(75,188)	(65,189)		(48,993)
Total stockholders' equity	16,335	4,596		12,089	$ 7,071
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 18,606	$ 7,431		$ 12,899

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Condensed Consolidated Balance Sheets
Preferred Stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	40,000,000	40,000,000	40,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	9,247,388	6,019,663	5,063,968
Common stock, shares outstanding	9,247,388	6,019,663	5,063,968

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Condensed Consolidated Statements of Operations and Comprehensive Loss
Net sales	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Operating expenses
Selling, general and administrative	1,495	1,430	5,004	3,250
Research and development	1,802	3,273	5,755	7,939
Total operating expenses	3,297	4,703	10,759	11,189
Loss from operations	(3,297)	(4,703)	(10,759)	(11,189)
Interest income	1	31	30	228
Loss before income taxes	(3,296)	(4,672)	(10,729)	(10,961)
Income tax benefit			(730)
Net loss	$ (3,296)	$ (4,672)	$ (9,999)	$ (10,961)
Basic and diluted loss per share (in dollars per share)	$ (0.42)	$ (0.84)	$ (1.49)	$ (2.09)
Weighted average shares outstanding - basic (in shares)	7,789	5,582	6,727	5,249
Weighted average shares outstanding - diluted (in shares)	7,789	5,582	6,727	5,249
Comprehensive loss	$ (3,296)	$ (4,672)	$ (9,999)	$ (10,961)

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Cash flows used in operating activities:
Net loss	$ (3,296)	$ (4,672)	$ (9,999)	$ (10,961)	$ (16,196)	$ (7,600)
Adjustments to reconcile net loss to cash flows used in operating activities:
Depreciation and amortization	36	4	98	25	50	32
Loss on disposal of plant and equipment			63	6
Stock-based compensation expense			907	555	939	78
Expense for warrants issued in conjunction with service agreement			160
Changes in assets and liabilities
Accounts receivable				259	258	(123)
Other current assets			(321)	(24)	(166)	(94)
Accounts payable and accrued expenses			(574)	480	2,026	496
Net cash used in operations			(9,666)	(9,660)	(13,089)	(7,211)
Cash flows used in investing activities:
Purchases of property and equipment			(132)	(34)	(451)	(7)
Net cash used in investing activities			(132)	(34)	(451)	(7)
Cash flows provided by financing activities:
Net proceeds from the sale of common stock			20,620	7,650	7,627	11,917
Net cash provided by financing activities			20,620	7,650	7,627	11,917
Effect of exchange rate changes in cash			61	38	126	623
Net increase (decrease) in cash and cash equivalents			10,883	(2,006)	(5,787)	5,322
Cash and cash equivalents - beginning of period			6,563	12,350	12,350	7,028
Cash and cash equivalents - end of period	$ 17,446	$ 10,344	$ 17,446	$ 10,344	$ 6,563	$ 12,350

Nature of Business and Significant Accounting Policies

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Nature of Business and Significant Accounting Policies

Nature of Business and Significant Accounting Policies

Note 1 - Nature of Business and Significant Accounting Policies

Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Recently Adopted Accounting Pronouncements

There was no other accounting pronouncement adopted during the three-month period ended September 30, 2012 that had a material impact on our financial position, operating results or disclosures.

Recent Accounting Pronouncements to be Adopted

Note 1—Nature of Business and Significant Accounting Policies

Going Concern: The Company's financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, "Sunshine Heart" or the "Company"). All inter-company accounts and transactions between consolidated entities have been eliminated.

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Other Current Assets: Other current assets represent prepayments and deposits made by the Company.


Office furniture and equipment		5-15 years
Computer software and equipment		3-4 years
Laboratory and research equipment		3-15 years
Production equipment		7 years

Depreciation expense was $49 and $32 for the years ended December 31, 2011 and 2010, respectively.

Comprehensive Income (Loss): The components of comprehensive income (loss) include net income (loss) and the effects of foreign currency translation adjustments.

See Note 3 for further information regarding the assumptions used to calculate the fair value of share-based compensation.

Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 2,216,615 and 1,310,987 for the years ended December 31, 2011 and 2010, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company's net loss in each of those years.

- Definition

+ References + Details

Equity

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Equity

Equity

Note 2 — Equity

Private Placement

On February 8, 2012 we placed 256,875 shares of common stock (in the form of CDIs) at AU$8.00 per share, for proceeds, net of transaction costs of $2,061.

Public Offering

Stock-Based Compensation

Warrants

Warrants to purchase 1,664,599 and 1,496,032 shares of common stock were outstanding at September 30, 2012 and December 31, 2011, respectively.

Note 3—Equity

Private Placement

In November and December, 2010, the Company placed 2,368,576 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $11,917.

In January 2011, the Company placed 17,858 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $99.

In July 2011, the Company placed 572,222 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $4,597.

In September 2011, the Company placed 349,444 shares of common stock (in the form of CDIs) for proceeds, net of transaction costs, of $2,838.

Stock Options

	December 31, 2011		December 31, 2010

Selling, general and administrative	$	621	$	55
Research and development		318		23

Total	$	939	$	78

The following is a summary of the Plan and non-Plan stock option activity during the year ended December 31, 2011 and 2010.

		Weighted Average Exercise price			Aggregate Intrinsic Value

Outstanding, December 31, 2009	78,789	$	37.94
2010 Grants	50,000		10.72
2010 Exercises	—		—
2010 Forfeitures/expiration	2,091		36.70

Outstanding, December 31, 2010	126,698		28.00	7.26	$	819

Exercisable at December 31, 2010	90,427		6.94	6.54		819
2011 Grants	794,926		7.64
2011 Exercises	1,560		6.58
2011 Forfeitures/expiration	33,231		13.02

Outstanding, December 31, 2011	886,833	$	10.05	9.21	$	62,674

Exercisable at December 31, 2011	184,296	$	18.74	10.06	$	24,013

The weighted-average fair value of stock options granted during the years ended December 31, 2011 and 2010 was $6.62 and $10.72, respectively.

	Year ended December 31

	2011			2010
Expected dividend yield		0	%		0	%
Risk-free interest rate		1.43	%		4.97	%
Expected volatility		100	%		65	%
Expected life (in years)		6.5			5

Warrants

Warrants to purchase 1,496,032 and 1,223,787 shares of common stock were outstanding at December 31, 2011 and 2010, respectively.

On November 10, 2010, the Company issued 357,050 warrants at an exercise price of AU$6.40 and a term of 4 years as part of the private placements previously described.

During the year ended December 31, 2011, 14,879 warrants were exercised at a price of AU$6.40 for total proceeds of $99.

Balance Sheet Information

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Balance Sheet Information

Balance Sheet Information

Note 3 - Balance Sheet Information

Property, Plant and Equipment

Property, plant and equipment were as follows:

	September 30, 2012			December 31, 2011

Library	$	1		$	1
Office Furniture & Fixtures	98			177
Leasehold Improvements	145			251
Software	9			37
Production Equipment	384			293
Computer Equipment	141			134
Total	778			893
Accumulated Depreciation	(285		)	(371		)
	$	493		$	522

Depreciation expense for the three and nine month periods ended September 30, 2012 and 2011 was $36, $4, $98 and $25, respectively.

Note 2—Balance Sheet Information

Property, Plant and Equipment

Property, plant and equipment were as follows:

	December 31, 2011			December 31, 2010

Library	$	1		$	1
Office Furniture & Fixtures		177			90
Leasehold Improvements		251			78
Software		37			28
Production Equipment		293			179
Computer Equipment		134			65

Total		893			441
Accumulated Depreciation		(371	)		(321	)

	$	522		$	120

Income Taxes

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Income Taxes

Income Taxes

Note 4 — Income Taxes

Note 4—Income Taxes

Domestic and foreign loss before provision for income taxes consists of the following:



Domestic	(11,252	)	(2,207	)
Foreign	(4,944	)	(5,563	)

Total	(16,196	)	(8,270	)

The components of income tax expense for the years ended December 31, 2011 and 2010 consist of the following:



Income tax provision:
Current:
United States and state	(115	)	—
Foreign	—		(670	)
Deferred:
United States and state	—		—
Foreign	—		—

Total income tax (benefit) expense	(115	)	(670	)

Actual income tax expense differs from statutory federal income tax benefit for the years ended December 31, 2011 and 2010 as follows:



Statutory federal income tax benefit	(5,555	)	(2,812	)
State tax benefit, net of federal taxes	(727	)	(417	)
Foreign tax	199		225
R&D tax credit rebate	(265	)	(670	)
Valuation allowance increase	6,121		3,033
Other	112		(29	)

Total income tax (benefit) expense	(115	)	(670	)

Deferred taxes as of December 31, 2011 and 2010 consist of the following:



Deferred tax assets (liabilities):
Accrued expenses	115		120
Stock based compensation	658		385
Capitalized patent costs	126		140
Deferred rent	78		—
Fixed assets	(76	)	—
R&D credits	150		—
Other	7		7
Net operating losses	22,357		16,210

	23,415		16,862
Less: valuation allowance	(23,415	)	(16,862	)

	—		—

- Definition

+ References

+ Details

Nature of Business and Significant Accounting Policies (Policies)

9 Months Ended

12 Months Ended

Sep. 30, 2012

Dec. 31, 2011

Nature of Business and Significant Accounting Policies

Nature of Business

Going Concern

Going Concern: The Company’s financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Going Concern: The Company's financial statements have been prepared and presented on a basis assuming it continues as a going concern.

Basis of Presentation

Basis of Presentation: The accompanying consolidated financial statements include the accounts of Sunshine Heart, Inc. and its wholly-owned subsidiary, Sunshine Heart Company Pty Ltd. (collectively, "Sunshine Heart" or the "Company"). All inter-company accounts and transactions between consolidated entities have been eliminated.

Unaudited Interim Consolidated Financial Information

Use of Estimates

Net Loss per Share

Net Loss per Share: Basic net loss attributable to common stockholders, on a per share basis, is computed by dividing income available to common stockholders (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued and computed in accordance with the treasury stock method. In addition, in computing the dilutive effect of convertible securities, the numerator is adjusted to add back the after-tax amount of interest recognized in the period associated with any convertible debt. Shares reserved for outstanding stock warrants and options totaling 2,216,615 and 1,310,987 for the years ended December 31, 2011 and 2010, respectively, were excluded from the computation of loss per share as their effect was antidilutive due to the Company's net loss in each of those years.

Fair Value of Financial Instruments

Level 1: Financial instruments with unadjusted quoted prices listed on active market exchanges.

Recently Adopted Accounting Pronouncements

Recently Adopted Accounting Pronouncements

There was no other accounting pronouncement adopted during the three-month period ended September 30, 2012 that had a material impact on our financial position, operating results or disclosures.

Recent Accounting Pronouncements to be Adopted

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References + Details

Balance Sheet Information (Tables)

9 Months Ended

Sep. 30, 2012

Balance Sheet Information

Schedule of property, plant and equipment

	September 30, 2012			December 31, 2011

Library	$	1		$	1
Office Furniture & Fixtures	98			177
Leasehold Improvements	145			251
Software	9			37
Production Equipment	384			293
Computer Equipment	141			134
Total	778			893
Accumulated Depreciation	(285		)	(371		)
	$	493		$	522

Nature of Business and Significant Accounting Policies (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Going Concern
Accumulated deficit	$ 75,188		$ 65,189	$ 48,993
Stock warrants
Antidilutive securities
Outstanding stock excluded from the computation of loss per share as their effect was antidilutive	2,551,456	2,551,456	2,216,615	2,216,615
Stock options
Antidilutive securities
Outstanding stock excluded from the computation of loss per share as their effect was antidilutive	2,216,615	2,216,615	1,310,987	1,310,987

- Definition

+ References

+ Details

Equity (Details) $ / shares in Units, $ in Thousands				1 Months Ended				2 Months Ended	9 Months Ended		12 Months Ended
Equity (Details) $ / shares in Units, $ in Thousands	Aug. 20, 2012 $ / shares shares	Aug. 15, 2012 $ / shares shares	Feb. 08, 2012 USD ($) shares	Aug. 31, 2012 USD ($)	Sep. 30, 2011 USD ($) shares	Jul. 31, 2011 USD ($) shares	Jan. 31, 2011 USD ($) shares	Dec. 31, 2010 USD ($) shares	Sep. 30, 2012 USD ($)	Sep. 30, 2011 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Feb. 08, 2012 $ / shares
Private Placement
Issuance of common stock, net (in shares) \| shares		2,875,000	256,875		349,444	572,222	17,858	2,368,576
Common stock offering price (in dollars per share) \| (per share)	$ 7.00	$ 7.00											$ 8.00
Proceeds from private placement offering net of transaction costs			$ 2,061	$ 18,552	$ 2,838	$ 4,597	$ 99	$ 11,917	$ 20,620	$ 7,650	$ 7,627	$ 11,917
Public Offering
Issuance of common stock, net (in shares) \| shares		2,875,000	256,875		349,444	572,222	17,858	2,368,576
Common stock offering price (in dollars per share) \| (per share)	$ 7.00	$ 7.00											$ 8.00
Shares issued upon exercise of over-allotment options by underwriters \| shares	94,800
Proceeds from offering, net of transaction costs			$ 2,061	$ 18,552	$ 2,838	$ 4,597	$ 99	$ 11,917	20,620	7,650	7,627	11,917
Stock-Based Compensation
Compensation expense											939	78
Selling, general and administrative expense
Stock-Based Compensation
Compensation expense									594	385	621	55
Research and development expense
Stock-Based Compensation
Compensation expense									$ 313	$ 170	$ 318	$ 23

Equity (Details 2) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
Equity (Details 2) - USD ($) $ in Thousands	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Stock_Based Compensation
Unrecognized compensation costs related to non-vested stock option awards	$ 3,321	$ 4,582	$ 94
Unrecognized compensation costs related to non-vested stock option awards, recognition period	3 years 6 months	9 years 2 months 16 days	1 year 2 months 8 days
Grants (in shares)	31,875
Weighted average fair value of options granted	$ 196
Expected dividend yield (as a percent)	0.00%	0.00%	0.00%
Expected stock price volatility (as a percent)		100.00%	65.00%
Risk-free interest rate (as a percent)		1.43%	4.97%
Expected life	6 years 6 months	6 years 6 months	5 years
Vesting period of options	4 years
Contractual life of options	10 years
Shares authorized for grant	1,032,741
Minimum
Stock_Based Compensation
Expected stock price volatility (as a percent)	98.30%
Risk-free interest rate (as a percent)	1.38%
Vesting period of options		1 year
Maximum
Stock_Based Compensation
Expected stock price volatility (as a percent)	98.60%
Risk-free interest rate (as a percent)	1.43%
Vesting period of options		4 years

Equity (Details 3) $ in Thousands, $ in Thousands		1 Months Ended	9 Months Ended
Equity (Details 3) $ in Thousands, $ in Thousands	Sep. 07, 2012 USD ($) $ / shares shares	Feb. 29, 2012	Sep. 30, 2012 USD ($) $ / shares shares	Sep. 30, 2012 AUD ($) $ / shares shares	Feb. 08, 2012 $ / shares shares	Dec. 31, 2011 shares	Dec. 31, 2010 shares
Warrants
Warrants outstanding (in shares) \| shares			1,664,599	1,664,599		1,496,032	1,223,787
Warrants issued (in shares) \| shares			1,050	1,050
Exercise price of warrants (in dollars per share) \| $ / shares			6.40	6.40
Total proceeds \| $				$ 7
Expense for warrants issued in conjunction with service agreement \| $			$ 160
Warrant with four year term
Warrants
Warrants issued (in shares) \| shares					77,063
Exercise price of warrants (in dollars per share) \| $ / shares					11.20
Term of warrants		4 years
Warrant with five year term
Warrants
Warrants issued (in shares) \| shares	100,000				8,553
Exercise price of warrants (in dollars per share)	7.00				8.00
Term of warrants	5 years	5 years
Expense for warrants issued in conjunction with service agreement \| $	$ 160
Total fair value of warrants issued \| $	$ 519

Balance Sheet Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment
Total	$ 778		$ 778		$ 893	$ 441
Accumulated Depreciation	(285)		(285)		(371)	(321)
Property, plant and equipment, net	493		493		522	120
Depreciation expense	36	$ 4	98	$ 25	50	32
Library
Property, Plant and Equipment
Total	1		1		1	1
Office Furniture & Fixtures
Property, Plant and Equipment
Total	98		98		177	90
Leasehold Improvements
Property, Plant and Equipment
Total	145		145		251	78
Software
Property, Plant and Equipment
Total	9		9		37	28
Production Equipment
Property, Plant and Equipment
Total	384		384		293	179
Computer Equipment
Property, Plant and Equipment
Total	$ 141		$ 141		$ 134	$ 65

Income Taxes (Details) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Jun. 30, 2012	Sep. 30, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Taxes
Tax credit	$ (730)	$ (730)	$ (115)	$ (670)